Table 4.
Summary of microscopy-negative and PCR-negative specimens in proven and probable cases according to EORTC/MSG criteriaa
| Patient no. (n = 12) | Clinical specimen | Fungal culture result | GM-EIAb result from serum/BAL fluid | Secondary antifungal prophylaxisc | EORTC/MSG criteria |
|---|---|---|---|---|---|
| 1 | Lung biopsy | A. flavus | + | Proven IFI | |
| 2 | Lung biopsy | Neg | −/++ | Probable IFI | |
| 3 | Lung biopsy | Neg | Neg | Voriconazole | Proven IFI (histopathology-confirmed diagnosis) |
| 4 | BAL fluid | Neg | +/++ | Probable IFI | |
| 5 | BAL fluid | Neg | + | Probable IFI | |
| 6 | BAL fluid | Neg | −/+ | Probable IFI | |
| 7 | BAL fluid | A. fumigatus | Not done | Probable IFI | |
| 8 | BAL fluid | A. terreus | + | Voriconazole | Probable IFI |
| 9 | Autopsy | A. terreus | +/++ | Proven IFI | |
| 10 | Autopsy | Mucor spp. | Not done | L-AMB | Proven IFI |
| 11 | Autopsy | Neg | Not done | L-AMB | Proven IFI |
| 12 | CNS | Candida glabrata (blood) | Neg | Proven IFI |
a
GM-EIA, galactomannan enzyme immunoassay; L-AMB, liposomal amphotericin B; IFI, invasive fungal infections; Neg, negative.
b
GM-EIA was performed in several patients from either serum or BAL fluid, or both serum/BAL fluid.
c
These patients received secondary antifungal prophylaxis due to the proof of IFI during the previous hospitalization; clinical signs and symptoms showed deterioration.